DR5 (death receptor 5), also known as CD262, TRAILR2, KILLER, and TRICK2, is a single pass type 1 transmembrane glycoprotein in the TNF receptor superfamily (TNFRSF10B).  DR5 contains an extracellular region with 3 TNFR cysteine-rich repeats and a cytoplasmic death domain (DD). DR5 is widely expressed in normal tissues with high levels in heart, peripheral blood lymphocytes, liver, pancreas, spleen, thymus, prostate, ovary, uterus, placenta, testis, esophagus, stomach and throughout the intestinal tract.  DR5 is very highly expressed in various tumor cell lines. DR5 is one of 5 receptors for TRAIL (tumor necrosis factor-related apoptosis inducing ligand), also known as Apo2L (Apo-2 ligand) and TNFSF10.  TRAIL preferentially induces apoptosis in tumor cell lines, but not in normal cells. TRAIL binds at least 5 different receptors with characteristic TNFR cysteine-rich repeats. DR5/TRAILR2 is most closely related to DR4/TRAILR1 sharing 59% amino acid identity within the cytoplasmic DD.  DR5 transduces cell death signal and induces apoptosis by recruiting a cytosolic death­inducing signaling complex (DISC) that includes the adaptor FADD and caspase 8 and caspase 10. DR5 also promotes the activation of NF-κB and plays an essential role in ER stress-induced apoptosis. Defects in DR5 may be a cause of head and neck squamous cell carcinomas (HNSCC).

DR5 (death receptor 5), also known as CD262, TRAILR2, KILLER, and TRICK2, is a single pass type 1 transmembrane glycoprotein in the TNF receptor superfamily (TNFRSF10B).  DR5 contains an extracellular region with 3 TNFR cysteine-rich repeats and a cytoplasmic death domain (DD). DR5 is widely expressed in normal tissues with high levels in heart, peripheral blood lymphocytes, liver, pancreas, spleen, thymus, prostate, ovary, uterus, placenta, testis, esophagus, stomach and throughout the intestinal tract.  DR5 is very highly expressed in various tumor cell lines. DR5 is one of 5 receptors for TRAIL (tumor necrosis factor-related apoptosis inducing ligand), also known as Apo2L (Apo-2 ligand) and TNFSF10.  TRAIL preferentially induces apoptosis in tumor cell lines, but not in normal cells. TRAIL binds at least 5 different receptors with characteristic TNFR cysteine-rich repeats. DR5/TRAILR2 is most closely related to DR4/TRAILR1 sharing 59% amino acid identity within the cytoplasmic DD.  DR5 transduces cell death signal and induces apoptosis by recruiting a cytosolic death­inducing signaling complex (DISC) that includes the adaptor FADD and caspase 8 and caspase 10. DR5 also promotes the activation of NF-κB and plays an essential role in ER stress-induced apoptosis. Defects in DR5 may be a cause of head and neck squamous cell carcinomas (HNSCC).

  

Product Details

 

Gene Symbol: DR5; CD262; KILLER; TRICK2; TRICKB; ZTNFR9; TRAILR2; TRICK2A; TRICK2B; TRAIL-R2; KILLER/DR5; TNFRSF10B

  

NCBI Gene ID: 8795

 

Uniprot Entry: O14763

 

Construct Details: The recombinant human DR5-Fc fusion is expressed as a 381 amino acid protein consisting of Ile56 - Pro208 region of DR5 (UniProt accession #O14763)  and a C-terminal Fc from human IgG1, which exists as a dimer under non-reducing conditions.  

   

Source: Human cells stably expressing human DR5-Fc and growing in chemical-defined media with no animal components or antibiotics

 

Deduced Amino Acid Sequence: 

        10         20         30         40         50         60 

ITQQDLAPQQ RAAPQQKRSS PSEGLCPPGH HISEDGRDCI SCKYGQDYST HWNDLLFCLR  

        70         80         90        100        110        120 

CTRCDSGEVE LSPCTTTRNT VCQCEEGTFR EEDSPEMCRK CRTGCPRGMV KVGDCTPWSD 

       130        140        150        160        170        180 

IECVHKESGT KHSGEVPAVE ETVTSSPGTP ASPSTGTHTC PPCPAPELLG GPSVFLFPPK 

       190        200        210        220        230        240 

PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL 

       250        260        270        280        290        300 

TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE EMTKNQVSLT 

       310        320        330        340        350        360 

CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS 

       370        380 

VMHEALHNHY TQKSLSLSPG K 

 

M.W.: Calculated molecular mass (kDa): 42.3; Estimated by SDS-PAGE under reducing condition (kDa): 50-55

 

Calculated PI: 5.98

 

Calculated extinction coefficients (M-1 cm-1, at 280nm): 50640

 

Purity: >95% judged by SDS-PAGE under reducing condition (see the gel image above, labeled as "DTT: +")

 

Formulation: Supplied at 0.5 mg/ml in sterile PBSpH7.4 (carrier & preservative free). The purified recombinant protein was labeled with Biotin (3-5 Biotin per molecule) using the standard procedure.

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method

 

Biological Activity: Binds to its ligand human TRAIL and inhibits TRAIL-mediated signaling activity including TRAIL-­induced cytotoxicity in L-929 mouse fibroblast cells.

 

 

  

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 3 months. The undiluted protein can be stored at 4°C for no more than 2 weeks.

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

 

1. J. Biol. Chem. 272:25417 (1997).

2. Science 277:815-818(1997). 

3. Immunity 7:821 (1997). 

4. EMBO J. 16:5386 (1997). 

5. J Immunol. 171: 1061 (2003).

6. J. Biol. Chem. 279:45495 (2004).

 

 

 

Documentation

 

Product datasheet (pdf) can be downloaded here: FCLSF53-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.